Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.

RPEP-087292024Lingvay, Ildiko; Deanfield, John; Kahn, Steven E; Weeke, Peter E; Toplak, Hermann; Scirica, Benjamin M; Rydén, Lars; Rathor, Naveen; Plutzky, Jorge; Morales, Cristobal; Lincoff, A Michael; Lehrke, Michael; Jeppesen, Ole Kleist; Gajos, Grzegorz; Colhoun, Helen M; Cariou, Bertrand; Ryan, Donna

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.

Diabetes care, 47(8), 1360-1369

View on PubMed ↗Publisher’s paper ↗

Citation

Lingvay, Ildiko; Deanfield, John; Kahn, Steven E; Weeke, Peter E; Toplak, Hermann; Scirica, Benjamin M; Rydén, Lars; Rathor, Naveen; Plutzky, Jorge; Morales, Cristobal; Lincoff, A Michael; Lehrke, Michael; Jeppesen, Ole Kleist; Gajos, Grzegorz; Colhoun, Helen M; Cariou, Bertrand; Ryan, Donna. (2024). Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.. Diabetes care, 47(8), 1360-1369. https://doi.org/10.2337/dc24-0764